4.

Clinical prognostic factors associated with PFS and OS analyzed by Kaplan-Meier survival analyses

Clinical factors	PFS					OS
	Median (95% CI)	Mean (95% CI)	No.	P		Median (95% CI)	Mean (95% CI)	No.	P
Age (year)				<0.001					<0.001
<50	N/A	48.1 (44.2−52.0)	179			N/A	54.3 (51.0−57.7)	180
≥50	15.0 (10.7−19.3)	31.5 (24.4−38.8)	56			39.0 (16.7−61.3)	40.4 (33.7−47.2)	56
Sex				0.801					0.746
Male	N/A	44.5 (39.8−49.2)	139			N/A	50.7 (46.7−54.7)	140
Female	58.0	43.9 (38.5−49.3)	96			N/A	51.7 (46.8−56.5)	96
KPS				<0.001					<0.001
≤80	18.0 (10.0−26.0)	32.8 (27.5−38.1)	100			47.0 (25.0−69.0)	43.1 (38.2−48.1)	101
>80	N/A	52.8 (48.6−57.0)	135			N/A	56.8 (53.1−60.4)	135
Removal degree				0.323					0.281
GTR	N/A	45.5 (41.4−49.7)	163			N/A	52.6 (49.0−56.2)	163
Non-GTR	58.0	40.9 (34.2−47.5)	72			N/A	47.9 (41.9−54.0)	73
Tumor size (cm)				0.182					0.188
<6	N/A	46.6 (41.7−51.5)	115			N/A	53.6 (49.4−57.7)	116
≥6	53.0	41.8 (36.7−46.9)	120			N/A	48.9 (44.3−53.5)	120
Tumor grade				<0.001					<0.001
WHO II	N/A	63.6 (61.2−66.1)	84			N/A	67.0 (65.3−68.7)	84
WHO III + IV	17.0 (10.0−24.0)	32.8 (28.4−37.3)	151			39.0 (26.9−51.1)	42.0 (37.9−46.2)	152
EGFRvIII expression				0.001					0.002
Low	N/A	47.8 (43.8−51.8)	162			N/A	54.5 (51.0−58.0)	163
High	16.0 (0.0−37.7)	35.1 (28.5−41.7)	73			50.0 (26.3−73.7)	43.8 (37.8−49.9)	73
EGFRvIII nuclear translocation				<0.001					<0.001
<7%	N/A	49.3 (45.1−53.5)	141			N/A	56.7 (53.3−60.2)	142
≥7%	23.0 (1.2−44.8)	35.8 (30.0−41.6)	94			47.5 (17.4−77.6)	42.9 (37.4−48.3)	94
1p/19q codeletion				<0.001					<0.001
Yes	N/A	58.5 (54.1−62.9)	84			N/A	62.5 (58.9−66.0)	84
No	25.0 (13.1−36.9)	36.2 (31.7−40.7)	151			48.0	44.8 (40.7−48.9)	152
IDH mutation				<0.001					<0.001
Table 4 (continued)